Overview
The most common inhibitory neurotransmitter in the central nervous system.
Indication
No indication information available.
Associated Conditions
- Brain Health
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2020/05/05 | N/A | Completed | Ministry of Health and Population, Egypt | ||
2019/10/30 | Phase 4 | Recruiting | Sherief Abd-Elsalam | ||
2018/09/24 | Phase 4 | Completed | Hospital Infantil Albert Sabin | ||
2016/10/10 | Not Applicable | UNKNOWN | Aalborg University | ||
2013/12/05 | Phase 1 | Completed | |||
2009/01/22 | Phase 1 | Terminated | |||
2005/09/22 | Phase 2 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| Poem Care EGT | 485205 | Medicine | A | 4/4/2025 | |
| Witsbb Grow Pro+ TalPlax™ Drink Stage 3 | 486946 | Medicine | A | 4/28/2025 | |
| G13+ Bone Growth | 471586 | Medicine | A | 12/3/2024 | |
| Witsbb L-Lysine growth capsule | 479325 | Medicine | A | 2/17/2025 |
Help Us Improve
Your feedback helps us provide better drug information and insights.